Donor-Derived Exosome Monitoring for Transplanted Organ Rejection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring transplanted organ status are invasive, costly, and lack sensitivity and specificity, particularly for detecting early acute rejection in heart and lung transplants.
Innovation Solution
The method involves obtaining a biological sample from a transplant recipient, isolating, purifying, and identifying donor-derived microvesicles, specifically exosomes, using markers such as MHC proteins or tissue-specific proteins, to monitor the status of transplanted organs non-invasively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive biopsy methods are used to monitor transplanted organ status, then measurement precision is improved, but ease of operation deteriorates and loss of time increases
Solution Approach 1:
The patent extracts and monitors donor-specific exosomes from recipient's blood samples as a non-invasive alternative to invasive biopsies. The method isolates exosomes carrying donor MHC proteins from circulating blood, enabling detection of organ rejection status without surgical intervention while maintaining high measurement precision through specific immunological assays
Solution Approach 2:
The patent uses donor-specific MHC proteins on exosomes as intermediary markers to indirectly monitor transplanted organ status. Instead of directly examining the transplanted organ through biopsy, the method detects exosomes released by donor cells into the recipient's circulation, serving as a non-invasive proxy for organ health status
2Reliability
If frequent monitoring is performed to detect early rejection, then reliability is improved, but loss of time and productivity deteriorate
Solution Approach 1:
The patent enables preliminary detection of rejection by monitoring exosomes before clinical symptoms manifest. By detecting donor-specific exosomes in blood samples, the method identifies early signs of rejection that precede overt organ dysfunction, allowing timely intervention without requiring frequent routine monitoring
3Measurement precision
If current monitoring methods are used, then ease of operation is maintained, but measurement precision and reliability deteriorate
Solution Approach 1:
The patent creates a universal monitoring approach that can be applied to various transplanted organs (kidney, heart, liver, lung) through a single blood sampling procedure. The method detects donor-specific exosomes regardless of organ type, providing high measurement precision and specificity while maintaining ease of operation through a non-invasive blood test rather than organ-specific procedures
Data Source
AI summary
This present disclosure relates to the use of donor organ-derived microvesicles to monitor the status of a transplanted organ in a subject. Accordingly, this disclosure provides for methods and kits for isolating, purifying and/or identifying donor organ-derived microvesicles from a biological sample of a subject. In certain embodiments, a method for isolating, purifying and/or identifying donor organ-derived microvesicles includes obtaining a biological sample from the subject and isolating, purifying or identifying a donor organ-derived microvesicle from the biological sample by the detection of a protein specific for the donor.